Stocks in Play: BioVaxys Technology Corp
Wednesday, May 7, 202510:27 AM EST - BioVaxys Technology Corp : Announces today they have entered into a Research Agreement to collaborate on the development of new cancer therapeutics based on BioVaxys' DPX™ Immune Educating Platform in combination with Sona's Targeted Hyperthermia Therapy™, a photothermal cancer therapy that uses highly targeted infrared light to treat solid tumors. The heat for THT is delivered to tumors using infrared light that is absorbed by Sona's proprietary biocompatible Gold Nanorod technology which elicits a strong immune response. BioVaxys Technology Corp (C.BIOV) shares were unchanged at 0.03.Stocks in Play: BioVaxys Technology Corp, Thu, 08 May 2025 03:42:06 EST
Recent Posts
Romanian Inflation Ends Tumultuous Year in Politics Close to 10%
UK Boosts Support For Offshore Wind in Bumper Auction
Ireland Is Trying to Get Back on the Data Center Bandwagon
Notice Concerning Change of Representative Executive Officer
Polish Recycler Bets Millions on Europe’s Critical Metals Push
Blistering Metals Rally Sends Silver, Tin and Copper to Records
Wellington Management Appoints Alex Behm to Strengthen Secondaries Capabilities
TCS and AMD Announce Strategic Collaboration to Drive AI Adoption at Scale
New data reinforces Ipsen’s commitment to bringing solutions and addressing care gaps in neurological diseases at TOXINS
TOXINS 2026: Clinical Updates on Galderma’s Leading Neuromodulator Portfolio Further Reinforce Its Leadership in Injectable Aesthetics
